Cargando…

Heterocyclic compounds as key structures for the interaction with old and new targets in Alzheimer’s disease therapy

Nowadays, Alzheimer’s disease (AD) is widely recognized as a real social problem. In fact, only five drugs are FDA approved for the therapy of this widespread neurodegenerative disease, but with low results so far. Three of them (rivastigmine, donepezil and galantamine) are acetylcholinesterase inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hiremathad, Asha, Piemontese, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607816/
https://www.ncbi.nlm.nih.gov/pubmed/28966636
http://dx.doi.org/10.4103/1673-5374.213541